faa glp 1 What You Need to Know About GLP-1 Drugs AME Minute: Why did FAA

GLP-1s are a specific type of medication first launched in 2005 for the treatment of type 2 diabetes

For those of us who live with these crushing problems, it seems too cruel to wait for the regulatory process to catch up

Single-cell mapping of GLP-1 and GIP receptor expression in the dorsal vagal complex

Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

Modern telehealth has made it possible to access high-quality, medically supervised care from the comfort of your home

Traditional weight loss methods often focus solely on caloric restriction and exercise, which may not address underlying factors like hormonal imbalances or appetite control